A Fresh Deal: How the Bioeconomy can cure inflation

Not a Green Deal. Not a New Deal. A fresh deal for consumers who want yesterday’s prices, tomorrow’s technologies, and a government that knows how to learn.

Here at The Digest, we spend 95 percent of our days in the weeds of bioreactors, offtake contracts, carbon intensity scores, and rack blenders. But all of it—the technologies, the projects, the capital, the promise—exists inside a much larger economic storm. Consumers are rebelling against the cost of living, and with good reason. If the bioeconomy can only tell a family struggling with grocery bills and gasoline prices how many grams of carbon dioxide it has avoided, it will remain a permanent niche, forever asking for another subsidy and another mandate. The challenge is not simply to make the bioeconomy sustainable. It is to make the household economy more affordable through the bioeconomy.

The morning after an election, Washington splits cleanly into two camps: those convinced the electorate has divinely endorsed their entire platform, and those convinced the voters were tragically swindled. Both sides parse exit polls and summon consultants to divine the will of the people.

Yet, there is no doubt what the American people were saying:

We want our old prices back.

Not a stimulus check that arrives on Tuesday only to be devoured by price hikes by Friday. Not another subsidy wrapped in four hundred pages of administrative rulemaking.

They simply want to wheel a cart through the grocery store, pick up a prescription at the pharmacy counter, fill the family car at the pump, and pay something resembling what they paid before global supply chains tied themselves into knots.

Economists will tell you, with impeccable econometric precision, that inflation has cooled. Prices are rising more slowly. This is welcome news, ruined only by basic arithmetic: if your grocery bill jumped 35 percent over three years,a deceleration in the rate of increase does not put meat back in the freezer. It merely guarantees that your purchasing power will be dismantled at a more dignified pace.

The consumer is not asking for a slower decline. The consumer is demanding an economic restoration.

What we need is neither a Green Deal nor a New Deal—revered though those traditions may be by their respective partisans. What we need is a Fresh Deal, anchored to a single, uncompromising truth: sustainability and affordability are not natural enemies. They are twin engines of the same locomotive, provided policy is engineered around real-world throughput rather than ideological purity.

A Green Deal asks how to make the economy more sustainable. A Fresh Deal asks how sustainability can make the economy more affordable.

What if Washington set aside the rhetorical thunder and gave itself a measurable scorecard: restore pre-pandemic affordability across the three pillars of the household budget—Energy, Food, and Medicine?

No price controls. No federal rationing. No wishful thinking. Just technology, industrial capacity, and market competition unleashed against avoidable scarcity.

Here is where the dealing starts.

1. Energy: A Global Ten Percent Revolution

When retail fuel prices spike, Washington routinely defaults to two moves: begging foreign oil cartels to open their valves, or threatening domestic petroleum executives with congressional hearings. Neither produces a single drop of fuel.

Meanwhile, petroleum refining remains a capital-heavy, permit-intensive business, with capacity limits in critical markets and new greenfield facilities expensive and agonizingly slow to build. Yet sitting across the American heartland, throughout the sugarcane fields of Brazil, and across industrial centers worldwide are commercialized renewable fuels capable of supplementing conventional petroleum supplies without waiting a decade for concrete to cure at a new refinery.

Ethanol. Biodiesel. Renewable diesel.

Here is the play: a global ten percent renewable fuels standard. E10 for gasoline, and a baseline ten percent renewable contribution to diesel, powered by biodiesel, drop-in renewable diesel, or technically appropriate combinations of both.

The United States has essentially completed its domestic transition to E10. But the global frontier remains enormous.For nations still burning unblended petroleum gasoline, shifting to E10 replaces a tenth of the finished fuel’s volume with renewable ethanol, reducing the petroleum-derived gasoline otherwise required. For diesel—the workhorse fuel of global commerce, agriculture, and freight—a ten percent renewable standard offers another pressure-release valve on refined distillate markets. Not every nation would use an identical formulation: biodiesel blending requires attention to vehicle compatibility, climate, and fuel specifications, while renewable diesel can be used at higher concentrations in compatible engines and infrastructure. The objective is a common level of ambition, not an identical recipe at every pump.

The economics begin with arbitrage. Ethanol competes with petroleum gasoline blendstock, delivering high-octane molecules whose value rises when petroleum-derived octane becomes expensive. Biodiesel and renewable diesel introduce additional competition against middle distillates, drawing on soybean oil, tallow, used cooking oil, and other renewable feedstocks. When agricultural and waste-derived molecules can be produced and delivered at an advantage over petroleum hydrocarbons, the marketplace has an opportunity to turn that price differential into consumer savings.Instead of relying exclusively on the economics of crude oil and petroleum refining, fuel buyers gain a second set of supply curves against which to negotiate.

The prize is a deep, liquid, multi-supplier global commodities market. American corn ethanol, Brazilian sugarcane fuel,and renewable diesel from agricultural oils and waste fats could trade across a much larger international marketplace.The United States exported 2.2 billion gallons of ethanol worth $4.7 billion in 2025; imagine that trade expanding as dozens of additional countries establish predictable demand for renewable fuels. Energy security becomes less dependent on negotiations with petroleum exporters and more responsive to competition among suppliers, feedstocks,and technologies.

And diesel matters far beyond the fuel pump. It moves the trucks carrying groceries, powers the agricultural equipment producing them, and supports the industrial operations that process them. A more competitive diesel market offers a second route toward lower food costs, complementing an effort to strip unnecessary expense out of the grocery supply chain.

At home, the next domestic step is obvious: nationwide, year-round E15, backed by a clear pathway toward higher-octane E30 blends where vehicles, infrastructure, and fuel standards permit, paired with modernized terminal rack-blending infrastructure.

Feedstocks are finite, food security must remain sacrosanct, and renewable fuels are not automatically cheaper than petroleum products. Agricultural prices can rise when fuel demand expands, and mandates can become costly when supply cannot keep pace. A blending target alone is not a magic wand. That is why the Fresh Deal measures its success in pump-price savings, refinery bottlenecks relieved, and net consumer purchasing power restored, not merely in compliance certificates traded.

We don’t need another white paper on energy independence. We need open markets, competing molecules, and gallons flowing to the rack.

2. Food: The 19-Cent Reality Check

Here is the most striking paradox in the American supermarket: food prices went through the roof, yet the farmer’s share of the retail grocery dollar is barely 19 cents.

Where did the other 81 cents go?

It went into the labyrinth between the furrow and the front register: food processing, packaging, freight logistics,refrigerated warehousing, distribution networks, retail operations, slotting fees, and the massive advertising budgets required to convince an exhausted shopper that one brand of rolled oats possesses a soul while the generic bag next to it does not.

Some of those costs are indispensable. Food must be processed safely, transported efficiently, and kept cold where necessary. But embedded in that enormous post-farm economy are substantial opportunities to eliminate unnecessary branding expense, SKU proliferation, distribution inefficiency, and shelf-space costs that add to the register receipt without adding nourishment to the family.

Branded goods have earned their shelf space; shoppers who want the prestige label should remain entirely free to buy it. But millions of working households would gladly trade the television commercials, the celebrity endorsements, and the lithographed cartons for thirty percent off the price of everyday essentials.

Private-label store brands have already proven the concept. It is time to turn that retail advantage into national industrial strategy.

The USDA already possesses a potential financing engine: the Commodity Credit Corporation (CCC), an established vehicle for supporting agricultural markets and maintaining adequate supplies. Use existing CCC authorities where applicable, and seek any additional statutory authorization needed, to launch a $2 billion competitive infrastructure challenge for affordable staple foods.

The mandate: finance efficient regional processing hubs, shared packaging facilities, and bulk distribution corridors designed to support low-cost, high-volume, standardized staple groceries. Manufacturers and grocers would compete for access to support by demonstrating how they could achieve pre-pandemic affordability benchmarks, backed by transparent pricing and independently auditable savings passed through to consumers.

This is not a government-run grocery brand. It is an industrial challenge to entrenched distribution and processing arrangements: build open-architecture supply chains for the basics—milk, flour, cooking oils, eggs, grains—and let competing businesses find the most efficient ways to deliver them. Not every product requires an advertising campaign,a premium carton, or a complicated journey through multiple intermediaries before reaching the shopping cart.

And make the public bargain explicit. Support continues only when participating companies demonstrate measurable consumer savings against independently established baselines. No verified savings, no continuing support. This is not industrial welfare disguised as innovation. It is public investment purchasing a measurable public outcome.

Let the shelf decide. Let the consumer vote with their cart.

3. Pharmaceuticals: Exchanging Calendar Time for Margin

The COVID-19 pandemic challenged an enduring assumption about pharmaceutical development: that the conventional calendar represents the fastest possible route from scientific discovery to an approved medicine.

Operation Warp Speed demonstrated that when clinical development activities overlap, regulatory engagement happens in real time, and manufacturing infrastructure is financed before final authorization, development calendars can sometimes be compressed dramatically without abandoning rigorous scientific evaluation. It required exceptional resources, substantial prior scientific work, and extraordinary coordination. But it proved that the organization of development itself is an opportunity for innovation.

Calendar time is carrying cost. Every avoidable month adds financing expense, consumes resources, delays potential revenues, and may shorten the effective commercial life remaining under patent protection. Those costs are not the sole explanation for high pharmaceutical prices, which also reflect patents, competition, manufacturing complexity,insurance arrangements, and distribution practices. But reducing unnecessary development time creates economic value. Why shouldn’t the consumer receive a share?

It is time to strike a clean commercial bargain: Speed in exchange for price.

Establish a voluntary Fast-Track Affordability Pathway, using existing FDA authorities where applicable and seeking additional authorization where necessary, for essential therapies, chronic-disease treatments, and high-impact biosimilars. In exchange for intensive regulatory coordination, efficient clinical development pathways, dedicated scientific consultation, and expedited review where justified by the evidence, participating manufacturers would agree to two binding conditions:

• Pre-pandemic affordability benchmarks: Prices anchored to verified historical or comparable-treatment affordability metrics, with enforceable commitments that deliver meaningful savings to patients rather than merely lowering a theoretical list price.

• Transparent distribution: Distribution arrangements designed to pass savings through to patients, including direct purchasing and cost-plus pharmacy models where appropriate, while addressing opaque rebate practices and ensuring that insured patients are not excluded from the benefits.

The objective is not to shorten clinical trials arbitrarily, eliminate safety requirements, or demand the same economics from an innovative cancer therapy and an established generic medicine. It is to create a voluntary pathway through which qualified companies can exchange greater development efficiency and regulatory coordination for measurable public affordability.

You want coordination that can take years off the journey from laboratory bench to pharmacy shelf? Bring the price down to earth. Trade development efficiency for household economic relief.

The Real Engine: Design–Build–Test–Learn

Now comes the institutional chorus:

What if ethanol logistics jam? What if consumers stick to national food brands? What if drug manufacturers refuse the affordability bargain?

Then you fix the design.

And then you fix it again.

Modern biotechnology and advanced manufacturing conquered technical frontiers using a foundational operating system: Design–Build–Test–Learn. You formulate a hypothesis, build the process, measure the yield, analyze the breakdown, and iterate until the unit economics work.

Washington operates on an entirely different cadence: Argue–Build–Argue–Discard. A program encounters friction on day ninety, and both political parties spend the next four years hosting hearings to determine who broke the original blueprint.

We need public policy that moves at industrial velocity. Run two-year pilot programs with appropriate legal authority.Establish transparent operational scorecards. Adjust the dials as evidence accumulates. If an intervention doesn’t move the price needle, sunset it without apology. If a $2 billion food infrastructure initiative returns $10 billion in demonstrable consumer purchasing power, scale it across twenty states.

Measure outcomes, not bureaucratic motion. Stop counting pages of regulations, ribbons cut, and grants disbursed.Count gallons pumped, grocery bills lowered, prescriptions filled, and real dollars restored to household budgets.

And preserve the safeguards that matter. Clinical safety standards, food quality requirements, public accountability, and meaningful regulatory oversight are not obstacles to learning; they are conditions for doing it responsibly. The opportunity lies in accelerating coordination, eliminating unnecessary delays, and permitting well-designed experiments to generate real-world evidence faster than another decade of argument.

There is nothing sacred about an initial policy design. There is everything sacred about the public objective.

This is the path to rehabilitating the concept of sustainability. For decades, sustainability has too often been marketed to the public as a penance—a financial and operational sacrifice required to atone for industrial progress. But a sustainable technology that lowers production costs, expands the resource base, and drives prices down is not a sacrifice.

It is abundance. It is progress. And it turns clean technology from a policy mandate into a commercial imperative.

A Better Hand

Every two years, Washington shuffles the deck and deals out a new crop of fresh faces. Some wear red jerseys, some blue, and most will discover by their second month that fiery floor speeches do not drop the price of a gallon of diesel or a carton of eggs.

The public is not demanding an ideological crusade. They are asking for a government smart enough to deploy the extraordinary technologies already sitting on our laboratory benches, in our silos, and across our manufacturing plants.

We have the feedstocks in our fields and the biofuels in our tanks. We have the agricultural capacity to feed continents.We possess the finest biomedical infrastructure ever assembled.

What we need is the commercial courage to cut the deck, throw out the stale hands, and deal consumers around the world the winning cards they deserve.

Category: Top Stories